Eosinophilic Esophagitis

The American Gastroenterology Association, or AGA, has published new guidelines on the treatment of eosinophilic esophagitis in children and adults. It was the top story in gastroenterology last week.

The American Gastroenterological Association published new guidelines focused on the treatment of children and adults with eosinophilic esophagitis.

The tablet formulation of fluticasone was safe and well tolerated in adolescents and adults with eosinophilic esophagitis.

A number of high-profile, but ultimately weakly associated, risks have hounded proton pump inhibitors for years. The mainstream media caught on to research that linked the drugs to scary conditions such as dementia, myocardial infarction and even malignancies causing some patients to discontinue them entirely. However, new research over the last several years has either disproven those previous claims or found the associations to be extremely weak. How can the gastroenterology community rebuild the image of PPIs?

Healio Gastroenterology and Liver Disease compiled a list of the top five stories posted in October.

SAN ANTONIO — In this exclusive video from the American College of Gastroenterology Annual Meeting, Ikuo Hirano, MD, FACG, a professor of medicine at Northwestern University Feinberg School of Medicine, discusses his presentation of a phase 3 study on the efficacy of budesonide oral suspension for eosinophilic esophagitis.

SAN ANTONIO — Starting this weekend, Healio Gastroenterology and Liver Disease will provide live coverage as the exclusive media partner of the American College of Gastroenterology’s 84th Annual Scientific Meeting.

Two advancements in eosinophilic esophagitis — the success of the biologic therapy Dupixent in reducing symptoms and improving quality-of life, and the accuracy of a minimally invasive diagnostic test in distinguishing active vs. inactive disease — were among the stop stories in gastroenterology last week.

A minimally invasive diagnostic test that used a capsule attached to a string accurately distinguished active from inactive eosinophilic esophagitis in just 1 hour, according to results of a prospective study.

Patients with eosinophilic esophagitis who received Dupixent experienced improvement in dysphagia, severity of histologic and endoscopic features, esophageal intraepithelial eosinophil count and esophageal distensibility, and started seeing improved symptoms and quality of life, according to study results.